Use of CHO cell line with knockdown of SUV39h1 expression, and recombinant protein expression system

By using shRNA expression vector and SSR recombinase technology that targets the SUV39H1 gene in CHO cell lines, knocking down SUV39H1 expression solves the problem of low recombinant protein expression in CHO cell lines, significantly improves the expression level of recombinant protein, and achieves stability and efficient recombinant protein expression.

WO2024244614A1PCT designated stage expired Publication Date: 2024-12-05XINXIANG MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/081843
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-03-15
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

There is a problem of significant decrease in expression in the expression of CHO cell lines in recombinant proteins, which leads to time-consuming and laborious screening of stable and efficient expression cell lines. There is no method for improving the expression of recombinant proteins by knocking down or silencing SUV39H1 expression in the prior art.

Method used

Using shRNA expression vector targeting the SUV39H1 gene, the expression of SUV39H1 in CHO cell lines was knocked down by RNAi technology, combined with SSR recombinase technology, the shRNA sequence was designed and inserted downstream of the U6 promoter, and the shRNA expression vector targeting the SUV39H1 gene was constructed. CHO cells were transfected to reduce SUV39H1 expression levels and increase the expression of recombinant proteins.

Benefits of technology

It significantly reduced the expression levels of SUV39H1 mRNA and protein, improved the expression levels of recombinant proteins, solved the problem of low expression levels in the CHO cell expression system, and achieved stable and efficient recombinant protein expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024081843_05122024_PF_FP_ABST
    Figure CN2024081843_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are the use of a CHO cell line with knockdown of SUV39H1 gene expression, and a recombinant protein expression system. An shRNA expression vector targeting SUV39H1 gene is constructed, SSR recombinase is used for achieving the efficient and stable transfection of the DNA vector of an interference sequence, and the integration of the shRNA vector into a cell genome is catalyzed, so that the interference efficiency can be significantly improved; the knockdown of SUV39H1 gene expression is used in a recombinant protein expression system, so that the expression level of the protein of interest can be significantly improved, and the problem of relatively low expression level of CHO cell expression system in the biopharmaceutical production process is effectively solved.
Need to check novelty before this filing date? Find Prior Art

Description

Application of CHO cell lines with knockdown of SUV39H1 expression and recombinant protein expression system Technical Field

[0001] The present invention belongs to the technical field of genetic engineering, and particularly relates to the application of a CHO cell line for knocking down SUV39H1 expression and a recombinant protein expression system. Background Art

[0002] Chinese Hamster Ovary (CHO) cells are the preferred mammalian expression system host cell for the production of recombinant protein drugs. However, significant decreases in recombinant protein expression are still a prominent problem during long-term culture, making the selection of stable and efficient CHO cell lines time-consuming and labor-intensive. Therefore, the construction of efficient CHO cell expression systems through genetic engineering methods for cell line modification is of great significance. Many studies have also reported that the expression of recombinant proteins in CHO cells as host cells can be improved by knocking out genes that affect the cells' ability to increase differentiation and growth, or by introducing exogenous genes that can promote cell proliferation and differentiation.

[0003] Epigenetic regulation, such as DNA methylation and histone methylation, plays a crucial role in gene transcriptional activity and gene expression silencing. Current research on the impact of DNA methylation on transgenic expression in CHO cells primarily focuses on promoter modification, such as mutating cytosines in the promoter region, using CpG-free or synthetic promoters, or inserting core CpG island elements into the promoter. Furthermore, cell engineering techniques such as gene knockout, gene overexpression, or gene silencing can also be used to alter gene expression levels related to recombinant protein expression or activity. In recent years, efforts have also emerged to modify CHO cells by silencing genes associated with DNA methylation. For example, patent CN110257340A discloses a CHO cell line deficient in the Dnmt3b gene. This cell line demonstrates that epigenetic modifications mediated by the missing DNA methyltransferase Dnmt3b are more closely linked to gene expression regulation. In the absence of selective pressure, exogenous protein expression is more stable and expression levels are significantly increased.

[0004] Trimethylation of lysine 9 at histone 3 (H3K9me3) is associated with gene repression and heterochromatin formation. The histone methyltransferase SUV39H1 primarily modifies H3K9 through trimethylation, leading to transcriptional silencing and significantly influencing heterochromatin formation and gene expression regulation. However, techniques for enhancing recombinant protein expression by knocking down or silencing SUV39H1 expression in CHO cell lines have not been reported.

[0005] Summary of the Invention

[0006] In order to overcome the defects of the prior art, one of the objectives of the present invention is to provide an application of an shRNA expression vector targeting the SUV39H1 gene in constructing a recombinant protein expression system, which can increase the expression level of the recombinant protein.

[0007] A second purpose of the present invention is to use a CHO cell line with knockdown of SUV39H1 expression as a host cell for recombinant protein expression, so as to increase the expression level of the recombinant protein.

[0008] At the same time, the third purpose of the present invention is to provide a recombinant protein expression system, using the CHO cell line with knockdown of SUV39H1 expression provided by the present invention as a host cell to increase the expression level of the recombinant protein.

[0009] In order to achieve the above-mentioned object of the invention, the technical solution adopted by the present invention is as follows:

[0010] Application of shRNA expression vector targeting SUV39H1 gene in constructing recombinant protein expression system.

[0011] Application of CHO cell lines with knockdown of SUV39H1 gene expression as host cells for recombinant protein expression.

[0012] Optionally, the recombinant protein is selected from adalimumab and human serum albumin.

[0013] A recombinant protein expression system is constructed by CHO cell line host cells, an shRNA expression vector targeting the SUV39H1 gene, and an expression vector containing a recombinant protein encoding gene.

[0014] Optionally, it also includes SSR recombinase (Site-specific Recombinase); the shRNA expression vector targeting the SUV39H1 gene includes an SSR element.

[0015] Optionally, the construction method includes first constructing a CHO cell line that knocks down SUV39H1 expression: co-transfecting the shRNA expression vector into a CHO cell line host cell under the action of a recombinase to obtain a host cell that knocks down SUV39H1 expression;

[0016] The expression vector containing the recombinant protein encoding gene is then transfected into host cells for knocking down SUV39H1 expression.

[0017] Alternatively, other construction methods may be used, including first transfecting an expression vector containing a recombinant protein encoding gene into a CHO cell line to obtain a recombinant protein low-expressing cell line; and then co-transfecting an shRNA expression vector targeting the SUV39H1 gene into the recombinant protein low-expressing cell line under the action of a recombinase.

[0018] Optionally, the method further includes first constructing an shRNA expression vector: designing shRNA according to the sequence of SUV39H1, and connecting and inserting the shRNA nucleic acid fragment into a starting vector having an SSR element.

[0019] Optionally, the sequence of the shRNA targeting the SUV39H1 gene is: 5'-GGTTAAGTGGCGTGGATATCCCTCGAGGGATATCCACGCCACTTAACC-3'.

[0020] Optionally, the starting vector is a piggy BAC vector.

[0021] Specifically, the nucleic acid fragment encoding shRNA is inserted downstream of the U6 promoter.

[0022] Beneficial effects of the present invention:

[0023] RNAi technology can highly specifically and selectively knock out the expression of target genes. By introducing shRNA into mammalian cells through vector transfection, shRNA can be stably integrated and the target gene can be knocked out long-term, thereby affecting the transcription and protein expression levels of the recombinant protein. The present invention uses RNAi technology to achieve SUV39H1 gene knockdown and silence SUV39H1 gene expression, which has the following beneficial effects:

[0024] 1) The present invention designs and synthesizes shRNA (5'-GGTTAAGTGGCGTGGATATCCCTCGAGGGATATCCACGCCACTTAACC-3') targeting the Chinese hamster SUV39H1 gene sequence, utilizes SSR recombinase to achieve efficient and stable transfection of the interference sequence DNA vector, catalyzes the integration of the shRNA vector into the cell genome, significantly improves the interference efficiency, and realizes the construction of a stable transfection cell line of the target gene SUV39H1;

[0025] 2) The present invention can significantly reduce the expression levels of SUV39H1 mRNA and protein in CHO cells through SSR gene recombination technology, and has a significant knockdown effect on the target gene;

[0026] 3) The SUV39H1 stable knockdown cell line constructed by the present invention has a growth capacity indistinguishable from that of normal cells. As a host cell for a recombinant protein expression system, it can significantly increase the expression level of the target protein, effectively solving the problem of low expression levels in CHO cell expression systems during biopharmaceutical production.

[0027] 4) At the same time, the examples of the present invention demonstrate that the expression level of the recombinant protein can be increased by transfecting the shRNA expression vector targeting the SUV39H1 gene into a recombinant protein expression system. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 shows the results of qPCR detection of SUV39H1 gene mRNA expression in SUV39H1 stable knockdown cell lines and control group cells;

[0029] Figure 2 shows the results of Digital Western (Jess) assay for SUV39H1 gene protein expression in SUV39H1 stable knockdown cell lines and control group cells;

[0030] FIG3 is a graph showing the protein expression results of recombinant adalimumab in SUV39H1 stable knockdown cell lines expressing adalimumab and control cells detected by ELISA;

[0031] FIG4 is a graph showing the results of detecting the expression of SUV39H1 gene protein in SUV39H1 stable knockdown cell lines expressing human serum albumin and control cells by Digital Western (Jess) assay;

[0032] FIG5 is a graph showing the results of ELISA detection of the protein expression of human serum albumin in the SUV39H1 stable knockdown cell line expressing human serum albumin and the control group cells. DETAILED DESCRIPTION

[0033] The present invention will be further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto;

[0034] Example 1 Construction of shRNA expression vector targeting SUV39H1 gene

[0035] The shRNA expression vector targeting the SUV39H1 gene in this embodiment is constructed by:

[0036] 1) According to the NCBI GenBank Chinese hamster SUV39H1 gene sequence (GeneID: 100764568) and the shRNA design principles, the shRNA encoding nucleic acid fragment sequence was designed to be 5'-GGTTAAGTGGCGTGGATATCCCTCGAGGGATATCCACGCCACTTAACC-3';

[0037] 2) Using the piggy BAC vector containing the SSR element (purchased from Haixing Biotechnology Co., Ltd.) as the starting vector, the nucleic acid fragment synthesized in step 1) was inserted downstream of the U6 promoter of the starting vector by enzyme digestion and ligation to construct an shRNA transposon vector containing the SSR element, i.e., an shRNA expression vector targeting the SUV39H1 gene.

[0038] Example 2 Construction of a CHO cell line with knockdown of SUV39H1 expression

[0039] This example provides a CHO cell line with knockdown of SUV39H1 expression. The specific steps of its construction process are as follows:

[0040] 1) Cell Culture Preparation: CHO-S cells were cultured in DMEM / F12 medium (containing 10% fetal bovine serum) in a constant temperature and humidity incubator at 37°C and 5% CO2. Recovered cells were passaged at least three times and the cell culture medium was changed the day before transfection. The day before transfection, trypsinized cells were plated in two wells of a 24-well plate. When the cells reached an optimal proliferation state at approximately 60% confluence, they were used for transfection. Before transfection, the medium was changed to double-antibody-free, low-serum medium.

[0041] 2) Cell transfection: Add 50 μL of double-antibody-free low-serum medium, 2.5 μg of vector and SSR recombinase to each well, add 50 μL of Opti-MEM medium, and add 2 μL of lipo2000 to the Opti-MEM medium and mix gently. Discard the culture medium of the cultured cells in the above 24-well plate, mix the incubated plasmid DNA and liposome mixture, and let it stand at room temperature for 5 minutes. Gently shake the culture dish back and forth to evenly distribute the mixture, mark it and record the time. Finally, place the culture plate containing the transfection complex and cells in a constant temperature incubator (37°C, 5% CO2) and culture overnight, then change to DMEM / F12 complete medium. 48 hours after transfection, use Puromycin for screening; after the cell confluence reaches 80%, subculture at a ratio of 1:2, and drug screening is carried out for 7-14 days.

[0042] 3) The experiment was divided into: shRNA1+SSR recombinase interference group (R1 group) and blank control group (control): the shRNA1+SSR recombinase interference group used the vector provided in Example 1 to perform cell transfection according to the above steps to obtain a SUV39H1 stable knockdown cell line (R1 group); the blank control group was a blank transfection without adding the vector to obtain a blank control cell line (control).

[0043] Example 3 Detection of effective shRNA interference efficiency

[0044] 1) qPCR experiments

[0045] Primers for qPCR detection of the target gene SUV39H1 and the internal reference gene GAPDH were designed and synthesized, as shown in Table 1:

[0046] Table 1 DNA primer sequence list

[0047] The SUV39H1 stable knockout cell line (R1) and the control group (control) were collected, and the mRNA was extracted by Trizol lysis and reverse transcribed into cDNA. The mRNA expression of the SUV39H1 gene in R1 and the control was detected using the SUV39H1 primer. The reaction system was 20 μL, and the reaction conditions were: 95℃ for 5 minutes; 95℃ for 10 seconds, 60℃ for 30 seconds, 40 cycles, and the internal reference for standardization was GAPDH, 2 -ΔΔCt As shown in Figure 1, the results showed that the mRNA expression of the SUV39H1 gene in the shRNA1+SSR recombinase interference group R1 was reduced to 26% of the control.

[0048] 2) Digital Western experiment

[0049] The Jess fully automatic protein expression analysis system (ProteinSimple) was used to detect the expression of SUV39H1 protein.

[0050] Prepare samples and antibodies: After lysing cells in each group, extract proteins and store them in lysis buffer. Determine protein concentration using a BCA kit.

[0051] Prepare the Jess instrument: First, turn on Jess and connect it to the computer, and then use Self-Test to perform a self-test of the Jess hardware.

[0052] Prepare reagents: Remove the PS-ST01-EZ-8 and DM-001 reagent kits, remove DTT powder and add 40 μL deionized water to prepare DTT solution; remove Master Mix powder and add 20 μL DTT solution and 20 μL 10× Sample Buffer to prepare 5× Master Mix (i.e., Loading Buffer); remove Ladder powder and add 20 μL deionized water to prepare Ladder (i.e., marker, molecular weight standard).

[0053] Add samples: Add 3 μL of sample (prepared with the Master Mix) to each well. Calculate the required total sample volume based on the final sample concentration and the number of wells. Denature the prepared sample in a 95°C water bath for 5 minutes. Place the primary antibody (10 μL / well) and secondary antibody (10 μL / well) on ice until ready to use. Prepare the luminescent solution by pipetting 200 μL each of Lumino-S and Peroxide and place on ice to protect from light.

[0054] Finally, add the prepared reagents to the plate using the reverse phase pipetting method according to the instructions. After balancing, centrifuge at 2500 rpm for 5 minutes at room temperature. Finally, load the plate into the Jess machine, remove the capillary tube and plate, and press Start to start the run.

[0055] As shown in Figure 2, Jess results showed that transfection of shRNA interference vector could significantly reduce the expression of SUV39H1 protein in the stable knockdown cell line.

[0056] Example 4 Construction of CHO cell proliferation assay for knockdown of SUV39H1 gene expression

[0057] Cell biological characteristics testing was used to verify whether the SUV39H1 knockdown CHO cell line could grow and be subcultured normally.

[0058] First, the cell morphology was observed under a microscope to see if it was normal, and the CCK-8 method (Cell Counting Kit-8, Beyotime Biotechnology Co., Ltd.) was used to detect cell proliferation: the cells in the R1 group and the control group were seeded in a 96-well plate, and the absorbance at a wavelength of 450 nm was measured using a microplate reader at 24, 48, and 72 h, respectively, to draw the growth curve.

[0059] The experimental results showed that CHO cells with knockdown of SUV39H1 gene expression were able to grow and proliferate normally.

[0060] Example 5 Recombinant protein expression

[0061] 1. Recombinant adalimumab (ADM)

[0062] 1) Construction of a stable knockdown cell line expressing adalimumab and detection of cell biological characteristics

[0063] To test the effect of SUV39H1 stable knockdown CHO cell lines on recombinant protein (antibody) expression, SUV39H1 stable knockdown cells (R1 group in Example 2) and CHO-S cells (control group in Example 2) were transfected with a eukaryotic expression vector expressing recombinant adalimumab. The transfected cell pool was stably selected using blasticidin for 14 days to construct SUV39H1 stable knockdown cells expressing ADM (ADM-R1) and control cells (control).

[0064] For adherent cultured ADM-R1 cells and control cells, cell proliferation was detected by CCK-8 assay. For suspension cultured cells, recombinant CHO cells (ADM-R1 and control) were plated in six-well plates at 3 × 10 5 Cells / mL were inoculated into chemically defined CD CHO medium (Henan Punuoyi Biological Products Research Institute Co., Ltd.) and cultured in suspension for 7 days. Cells were collected every day and the cells were stained with trypan blue. Cell viability and viable cell density were measured using a cell counter (Shanghai Ruiyu Biotechnology Co., Ltd.). The results showed that biological characteristics of ADM-R1 cells, such as growth status, morphology, cell proliferation, and viable cell density, were not significantly different from those of normal CHO cells.

[0065] 2) ELISA detection of recombinant ADM expression level

[0066] ADM-R1 cells and control cells cultured in suspension in chemically defined CD CHO medium for 7 days were centrifuged and the supernatants were collected on day 7. The expression of recombinant ADM was assayed by ELISA. As shown in Figure 3, the results showed that the expression level of recombinant ADM in the SUV39H1 stable knockdown cell line was increased by 1.45-fold compared to the control cell line.

[0067] 2. Human Serum Albumin (HSA)

[0068] 1) Construction of SUV39H1 stable knockdown cells expressing human serum albumin and detection of cell biological characteristics

[0069] The present invention uses a eukaryotic vector expressing recombinant human serum albumin to transfect CHO-S cells, and the transfected cell pool is stabilized for 14 days using blasticidin to obtain a CHO cell pool expressing HSA, and a low-expressing HSA monoclonal cell line (control) is obtained using a limiting dilution method;

[0070] The shRNA expression vector targeting the SUV39H1 gene constructed in Example 1 was transfected into the HSA low-expressing monoclonal cell line under the action of SSR recombinase, and the SUV39H1 stable knockdown cell line (HSA-R1) expressing HSA was obtained by Puromycin screening, as shown in FIG4 , wherein the control group was the HSA low-expressing monoclonal cell line;

[0071] The proliferation of adherent cultured HSA-R1 cells was detected by CCK-8 assay. For suspension cultured cells, HSA-R1 cells and HSA low-expressing monoclonal cells (control) were plated in six-well plates at a density of 3×10 5 The cells were inoculated with 100 cells / mL in CD CHO culture medium, and the viable cell density and cell viability were determined by trypan blue staining. The experimental results showed that there was no significant difference in the proliferation of HSA-R1 cells compared with the control group.

[0072] 2) ELISA detection of HSA expression changes

[0073] On day 7 of suspension culture, supernatants were collected by cryogenic centrifugation and ELISA was used to analyze changes in recombinant protein expression in the HSA-R1 SUV39H1 stable knockdown cell line and the control HSA low-expressing monoclonal cell line. As shown in Figure 5, the results showed that HSA expression levels in the SUV39H1 stable knockdown cell line increased by 2.63-fold compared to the control cell line.

[0074] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the various embodiments of the present invention.

Claims

1. Application of shRNA expression vector targeting SUV39H1 gene in constructing recombinant protein expression system.

2. Application of CHO cell lines with knockdown of SUV39H1 expression as host cells for recombinant protein expression.

3. The use according to claim 1, It is characterized in that The recombinant protein is selected from adalimumab and human serum albumin.

4. A recombinant protein expression system, It is characterized in that The vector is constructed by a CHO cell line host cell, a shRNA expression vector targeting the SUV39H1 gene, and an expression vector containing a recombinant protein encoding gene.

5. The recombinant protein expression system according to claim 4, It is characterized in that It also includes SSR recombinase; the shRNA expression vector targeting the SUV39H1 gene contains SSR elements.

6. The recombinant protein expression system according to claim 5, It is characterized in that The construction method comprises the following steps: firstly constructing a CHO cell line for knocking down the expression of SUV39H1: co-transfecting a shRNA expression vector targeting the SUV39H1 gene into a CHO cell line host cell under the action of a recombinase to obtain a host cell for knocking down the expression of SUV39H1; Then, the expression vector containing the recombinant protein encoding gene is transfected into the host cells for knocking down the expression of SUV39H1.

7. The recombinant protein expression system according to claim 5, It is characterized in that The construction method includes firstly transfecting an expression vector containing a recombinant protein encoding gene into a CHO cell line to obtain a recombinant protein low-expressing cell line; and then co-transfecting an shRNA expression vector targeting the SUV39H1 gene into the recombinant protein low-expressing cell line under the action of a recombinase.

8. The recombinant protein expression system according to claim 6 or 7, It is characterized in that The method also includes first constructing an shRNA expression vector: designing shRNA according to the sequence of SUV39H1, and connecting and inserting the shRNA nucleic acid fragment into a starting vector having an SSR element.

9. The recombinant protein expression system according to claim 6, It is characterized in that The sequence of the shRNA targeting the SUV39H1 gene is: 5'-GGTTAAGTGGCGTGGATATCCCTCGAGGGATATCCACGCCACTTAACC-3'.

10. The recombinant protein expression system according to claim 7, It is characterized in that The starting vector is a piggy BAC vector; the nucleic acid fragment encoding shRNA is inserted downstream of the U6 promoter.

Citation Information

Patent Citations

  • ShRNA (short hairpin ribonucleic acid) capable of inhibiting expression of buffalo SUV39H1 gene, lentiviral expression vector, construction method of lentiviral expression vector and applications of shRNA

    CN103497953A

  • Method for improving CHO cell recombinant protein expression level

    CN114214359A

  • Application of CHO cell line for knocking down SUV39H1 expression and recombinant protein expression system

    CN116790664A

  • Inhibitor of SUV39h1 histone methyltransferase for use in cancer combination therapy

    WO2018234367A1